You are here: Industry Insights > Amgen

News List

Amgen sinks after Q4 earnings miss despite tax benefits and plan for U.S. plant fiercepharma
February 05, 2018
Several pharma companies have thrilled investors with their sunny predictions of how the new business-friendly tax package will boost investors’ fortunes this year—but not Amgen.
Amgen Jumps as Migraine Drug Wows in Late-Stage Study biospace
January 24, 2018
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
How This Little Biopharma Could Beat Amgen, Teva to the Migraine Finish Line biospace
January 18, 2018
On Jan. 8, Alder BioPharmaceuticals announced that its eptinezumab met its primary endpoint in its Phase III PROMISE 2 clinical trial for preventing migraine.
UCB, Amgen’s Evenity under review in Europe pharmatimes
January 10, 2018
The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture.
FDA clears Amgen's bone drug for multiple myeloma pharmafile
January 09, 2018
Amgen has announced that the FDA has approved the indication expansion of its drug Xgeva to include the treatment of multiple myeloma, adding to its previous indication for the prevention of skeletal-related events in patients with bone metastases from s
These 2 Startups are Amgen's 2017 Golden Ticket Winners biospace
December 18, 2017
Amgen tapped the coveted 2017 Gold Ticket received by both companies at LabCentral. Grain Biological Products Company
FDA approves Amgen's Repatha (evolocumab) biospectrumasia
December 08, 2017
In the Repatha cardiovascular outcomes study (FOURIER), Repatha reduced the risk of heart attack by 27 percent, the risk of stroke by 21 percent and the risk of coronary revascularization by 22 percent
Amgen, Carmot ink backloaded $240M Parkinson’s pact fiercebiotech
December 07, 2017
Amgen has struck a deal with Carmot Therapeutics worth a potential $240 million.
Xencor Earns $10M Amgen Milestone contractpharma
December 06, 2017
Xencor has won a $ 10 million milestone bonus from Amgen
Mind-Blowing: Amgen's Aimovig Halves Length of Migraine Attacks in Phase III Study .biospace
December 01, 2017
Migraine sufferers may find some new relief as Amgen unveiled results from a late-stage study that shows its Phase III drug Aimovig reduced monthly migraine attacks in half.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page